从烟草中分离出的一种化合物对MPTP诱导的帕金森病C57BL/6小鼠模型的神经保护作用

Neuroprotection in the MPTP Parkinsonian C57BL/6 mouse model by a compound isolated from tobacco.

作者信息

Castagnoli K P, Steyn S J, Petzer J P, Van der Schyf C J, Castagnoli N

机构信息

Harvey W. Peters Center, Department of Chemistry, Virginia Tech, Blacksburg, Virginia 24061-0212, USA.

出版信息

Chem Res Toxicol. 2001 May;14(5):523-7. doi: 10.1021/tx000224v.

DOI:10.1021/tx000224v

PMID:11368550

Abstract

Epidemiological evidence suggests a lower incidence of Parkinson's disease in smokers than in nonsmokers. This evidence, together with the lower levels of brain monoamine oxidase (MAO) activity in smokers and the potential neuroprotective properties of MAO inhibitors, prompted studies which led to the isolation and characterization of 2,3,6-trimethyl-1,4-naphthoquinone (TMN), an MAO-A and MAO-B inhibitor which is present in tobacco and tobacco smoke. Results of experiments reported here provide evidence that this compound protects against the MPTP-mediated depletion of neostriatal dopamine levels in the C57BL/6 mouse. These results support the hypothesis that the inhibition of MAO by constituents of tobacco smoke may be related to the decreased incidence of Parkinson's disease in smokers.

摘要

流行病学证据表明，吸烟者患帕金森病的几率低于不吸烟者。这一证据，连同吸烟者大脑中单胺氧化酶（MAO）活性较低以及MAO抑制剂的潜在神经保护特性，促使开展了相关研究，最终分离并鉴定出2,3,6-三甲基-1,4-萘醌（TMN），一种存在于烟草和烟草烟雾中的MAO-A和MAO-B抑制剂。此处报告的实验结果证明，该化合物可防止C57BL/6小鼠中MPTP介导的新纹状体多巴胺水平耗竭。这些结果支持了以下假设：烟草烟雾成分对MAO的抑制作用可能与吸烟者帕金森病发病率降低有关。